Endogenous testosterone and endothelial function in postmenopausal women

Coronary Artery Disease

Volumn 18, Issue 1, 2007, Pages 9-13

  Montalcini, Tiziana ^a   Gorgone, Gaetano ^a   Gazzaruso, Carmine ^a   Sesti, Giorgio ^a   Perticone, Francesco ^a   Pujia, Arturo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Androgens; Cardiovascular disease; Flow mediated dilation; Sex hormones; Ultrasound

Indexed keywords

ANDROGEN; ESTROGEN; TESTOSTERONE;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BIOCHEMISTRY; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM; FEMALE; HORMONE ACTION; HUMAN; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; ULTRASOUND;

AGE DISTRIBUTION; AGED; BRACHIAL ARTERY; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; REGIONAL BLOOD FLOW; RISK FACTORS; TESTOSTERONE; VASODILATION;

EID: 33845787971     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000236290.79306.d1     Document Type: Article

References (43)

1. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. AHA medical/scientific statement: cardiovascular disease in women. Circulation 1993; 88 (4 Pt 1):1999-2009.
2. Colditz GA, Willett WC, Stampfer JJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk for coronary heart disease in women. N Engl J Med 1987; 316:1105-1110.
3. Kannel WG, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85:447-452.
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
5. Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333.
6. Sorva R, Kuusi T, Taskinen MR, Perheentupa J, Nikkila EA. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988; 69:191-197.
7. Jones DB, Higgins B, Billet JS, Price WH, Edwards CR, Beastall GH, et al. The effect of testosterone replacement on plasma lipids and apolipoproteins. Eur J Clin Invest 1989; 19:438-441.
8. Barrett-Connor E, Khaw KT, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med 1986; 315:1519-1524.
9. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men: a prospective population-based study. Circulation 1988; 78:539-545.
10. Yarnell JWG, Beswick AD, Sweetnam PM, Riad-Fahmy D. Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb 1993; 13:517-520.
11. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102:1906-1911.
12. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14:701-706.
13. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM, Rao DC. Evidence for an association between dehydroepiandrosterone sulfate and non-fatal, premature myocardial infarction in males. Circulation 1994; 89:89-93.
14. Marques-Vidal P, Sie P, Cambou J-P, Chap H, Perret B. Relationships of plasminogen activator inhibitor activity and lipoprotein (a) with insulin, testosterone, 17β-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab 1995; 80:1794-1798.
15. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K. Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 1993; 99:79-86.
16. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone: a study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 1988; 82:712-720.
17. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 1993; 8:261-269.
18. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997; 17:2192-2199.
19. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999; 84:813-819.
20. Chou TM, Sudhir K, Hutchinson SJ, Ko E, Amidon TM, Collins P, et al. Testosterone induces dilatation of canine coronary conductance and resistance arteries in vivo. Circulation 1996; 94:2614-2619.
21. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001; 103:1382-1385.
22. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100:1690-1696.
23. Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99:1666-1670.
24. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J 2002; 143:249-256.
25. Zitzmann M, Brune M, Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 2002; 87:5030-5037.
26. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 2000; 85:269-272.
27. Kang SM, Jang Y, Kim JY, Chung N, Cho SY, Chae JS, et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 2002; 89:862-864.
28. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS. Vascular reactivity is impaired in genetic females taking high dose androgens. J Am Coll Cardiol 1998; 32:1331-1335.
29. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001; 86:158-161.
30. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
31. Meredith IT, Yeung AC, Weidinger FF. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993; 87 (Suppl V):V-56-V-66.
32. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patient with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948-954.
33. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
34. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104:191-196.
35. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-1115.
36. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91:1314-1319.
37. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125:1-13.
38. Barrett-Connor EL. Testosterone and risk factors for cardiovascular disease in men. Diabetes Metab 1995; 21:156-161.
39. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78:539-545.
40. Rako S. Testosterone deficiency: a key factor in the increased cardiovascular risk to women following hysterectomy or with natural aging? J Womens Health 1998; 7:825-829.
41. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995; 91:1154-1160.
42. Oparil S, Levine RL, Chen YF. Sex hormones and the vasculature. In: Sowers JR, editor. Endocrinology of the vasculature. Totowa, New Jersey: Humana Press; 1996. pp. 225-227.
43. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A 2001; 98:3589-3593.